Tretinoin Capsules: Uses, Risks, and Oral vs. Topical

Tretinoin capsules are an oral form of all-trans retinoic acid (ATRA), prescribed almost exclusively for a specific blood cancer called acute promyelocytic leukemia (APL). Unlike the topical tretinoin creams and gels familiar to people treating acne or wrinkles, these capsules deliver the drug systemically at much higher doses to force immature leukemia cells to mature and stop multiplying. The treatment transformed APL from one of the deadliest forms of leukemia into one of the most curable, but the capsules carry serious risks that make close medical monitoring essential.

Why Tretinoin Capsules Exist

Most people associate tretinoin with skincare. The oral capsule version serves an entirely different purpose. APL is a subtype of acute myeloid leukemia in which white blood cells get stuck at an early stage of development and accumulate in the bone marrow. The hallmark of APL is a genetic rearrangement that produces an abnormal protein blocking the cells from maturing. Tretinoin, a derivative of vitamin A, overrides that block. Rather than killing cancer cells outright the way traditional chemotherapy does, it pushes those stuck cells to finish developing into normal-looking white blood cells that eventually die on their own schedule. This approach is sometimes called differentiation therapy.

The drug’s role in APL was established in the early 1990s. A landmark trial published in the New England Journal of Medicine concluded that tretinoin was a safe and highly effective agent for inducing complete remission in patients with APL.¹ Before tretinoin, APL was notorious for causing fatal bleeding episodes early in treatment. The introduction of oral tretinoin capsules shifted the survival picture dramatically.

How Effective Are They

When tretinoin capsules were first used as a single agent, complete remission rates in APL reached roughly 90 to 95 percent, which was a stunning leap from the results achievable with chemotherapy alone.² Over time, though, doctors found that remissions induced by tretinoin alone tended to be short-lived because patients often relapsed. The solution was combining tretinoin with other agents.

The current standard for many APL patients pairs tretinoin capsules with arsenic trioxide, another differentiation-based therapy. A randomized trial comparing this combination against the older approach of tretinoin plus chemotherapy found that all 77 evaluable patients in the tretinoin-arsenic trioxide group achieved complete remission, a 100 percent rate, compared with 95 percent in the chemotherapy combination group. Two-year event-free survival was 97 percent with the arsenic-based regimen versus 86 percent with chemotherapy, and overall survival was also better.³ The arsenic combination also caused fewer blood-count problems and fewer infections, although it did carry a higher risk of liver toxicity.

These numbers make APL one of the rare leukemias where the goal of treatment is genuine cure rather than long-term management. Tretinoin capsules are the backbone of that cure, but they are not a solo act.

Differentiation Syndrome

The most dangerous side effect of tretinoin capsules goes by the name differentiation syndrome, sometimes still called retinoic acid syndrome. It occurs precisely because the drug is working: as masses of leukemia cells suddenly begin maturing, they release inflammatory signals and can infiltrate organs, especially the lungs. Differentiation syndrome is life-threatening and can develop rapidly.

Characteristic features include breathing difficulty, unexplained fever, weight gain from fluid retention, fluid around the lungs or heart, low blood pressure, and kidney failure.⁴ In one case report, a patient developed fever, bleeding gums, bloody stool, and mouth ulcers shortly after starting tretinoin, followed within 36 hours by respiratory distress, dangerously low blood pressure, a racing heart, and plummeting oxygen levels.⁵ The speed of onset in that case underscores why patients starting tretinoin capsules are typically monitored closely, often in an inpatient setting.

Dexamethasone, a potent corticosteroid, is the main treatment once differentiation syndrome is suspected. Some treatment teams also give dexamethasone preventively, particularly in patients whose white blood cell counts are already elevated, though the evidence supporting routine prophylaxis is limited.⁶ The general approach is to start dexamethasone at the first hint of symptoms rather than waiting for a full-blown crisis, since delaying treatment raises the risk of death.

Pseudotumor Cerebri and Raised Intracranial Pressure

Tretinoin capsules can cause a condition called pseudotumor cerebri, in which pressure inside the skull rises without a tumor being present. Patients experience severe headaches, visual changes, and sometimes nausea or vomiting. The suspected mechanism involves vitamin A derivatives interacting with fatty components of structures in the brain that produce and absorb cerebrospinal fluid, leading to impaired drainage and a buildup of pressure.⁷

This side effect is not unique to tretinoin; other vitamin A-related drugs like isotretinoin (used for severe acne) also carry the risk. With tretinoin capsules, the doses used for leukemia are far higher than anything used in dermatology, which makes the risk more pronounced. Treatment for pseudotumor cerebri during tretinoin therapy usually starts with medications that reduce cerebrospinal fluid production, such as acetazolamide, and in some cases doctors switch to alternatives like topiramate if the first-line drug fails.

Pregnancy and Teratogenicity

Oral tretinoin is a powerful teratogen, meaning it causes birth defects. In animal studies, developmental abnormalities consistently appeared at doses well below those used in cancer treatment.⁸ The closely related drug isotretinoin is one of the most notorious causes of drug-induced birth defects in humans, and oral tretinoin carries the same fundamental risk because both compounds are retinoids that interfere with fetal development at the cellular level.

For this reason, pregnancy testing is required before starting tretinoin capsules, and patients who could become pregnant must use effective contraception throughout treatment and for some time afterward. This is non-negotiable in clinical practice, and it is one of the clearest absolute contraindications for the drug. The stakes are high enough that treatment teams document contraception counseling formally.

Why the Drug Stops Working Over Time

One of the peculiarities of tretinoin capsules is that the body develops a kind of tolerance to the drug fairly quickly. Patients who take tretinoin daily find that blood levels of the drug drop substantially within the first one to two weeks of treatment, even though the dose has not changed. Several mechanisms contribute to this decline: the gut may absorb less of the drug over time, the liver ramps up enzymes that break it down faster, and cells themselves produce binding proteins that soak up the drug before it can act.⁹

A key player in this accelerated breakdown is a family of enzymes called CYP26, particularly one form found in the liver. These enzymes specialize in clearing retinoic acid from the body, and tretinoin itself triggers their production, essentially training the body to eliminate the drug more efficiently with each passing day.¹⁰ This auto-induction is one reason why tretinoin alone does not produce lasting remissions. By the time a few weeks have passed, the drug has effectively told the body how to neutralize it.

This tolerance phenomenon also explains why treatment protocols do not rely on tretinoin capsules as indefinite maintenance therapy. Instead, the drug is given during the initial phase of treatment (induction) and sometimes during consolidation, but the core long-term remission is sustained by the partner agent, whether that is arsenic trioxide or chemotherapy. Doctors have explored adding drugs that block the CYP26 enzymes in an attempt to keep tretinoin levels high for longer, an approach touched on in solid tumor trials discussed below.

Drug Interactions Worth Knowing About

Because the liver enzymes that break down tretinoin belong to the cytochrome P450 system, drugs that inhibit or boost those enzymes can change how much tretinoin stays in the bloodstream. This matters clinically. In one reported case, a patient taking tretinoin capsules developed pseudotumor cerebri after starting voriconazole, an antifungal drug commonly prescribed to leukemia patients to prevent life-threatening fungal infections. The antifungal blocked the CYP enzymes that would normally clear tretinoin, causing drug levels to spike.¹¹

This kind of interaction puts physicians in a difficult position. APL patients are immunocompromised and often need antifungal coverage, but the very drugs that protect them from fungal infections can amplify tretinoin’s toxicity. Treatment teams work around this by monitoring closely for side effects, adjusting tretinoin doses if necessary, or choosing antifungals with less CYP450 impact when possible. Patients should make sure every prescriber involved in their care knows they are taking tretinoin capsules, because even common medications can shift drug levels in unexpected ways.

When Patients Cannot Swallow the Capsules

Tretinoin capsules are soft gelatin capsules, and no intravenous formulation is commercially available in most countries. This creates a real problem when patients are too sick to swallow, which is not uncommon in the initial days of APL treatment, particularly for patients in intensive care on mechanical ventilation. Clinicians have developed workarounds: the capsule contents can be extracted and diluted in water, then administered through a nasogastric or nasoenteral feeding tube. In one published case, this approach was used successfully without clogging the tube, and the patient achieved complete remission.¹²

This is not an FDA-approved route of administration, and the pharmacokinetics may differ from standard oral dosing. But in a disease where delays in starting treatment can be fatal, getting tretinoin into the patient by any safe method is a clinical priority. Staff handling the capsule contents also need to take precautions, since tretinoin is classified as a cytotoxic agent and can pose risks through skin contact or inhalation of aerosols during preparation.

Why Tretinoin Capsules Did Not Work for Other Cancers

After the success in APL, researchers logically wondered whether oral tretinoin could help with solid tumors, including cancers of the lung, breast, and other organs. Phase I trials tested escalating doses in patients with various advanced cancers, with daily oral doses ranging from 45 to 200 milligrams per square meter of body surface area.¹³ The results were discouraging. Even when ketoconazole was added to block the CYP enzymes and slow tretinoin breakdown, keeping blood levels higher for longer, no objective tumor shrinkage was seen in any of the patients treated.¹⁴

The reason goes back to why tretinoin works in APL in the first place. APL has a very specific genetic abnormality involving the retinoic acid receptor, which means the cancer is uniquely vulnerable to a drug that acts through that receptor. Most other cancers lack that particular vulnerability. Flooding the body with retinoic acid does not force their cells to differentiate in the same way. Research into retinoids for cancer prevention and treatment continues in various forms, but oral tretinoin capsules remain a niche drug with one blockbuster indication and little proven utility elsewhere.

How Tretinoin Capsules Differ from Topical Tretinoin

The confusion between oral and topical tretinoin trips up patients and sometimes even prescribers unfamiliar with oncology. Both contain the same active molecule, all-trans retinoic acid, but the similarities essentially end there. Topical tretinoin is applied to the skin at concentrations of 0.025 to 0.1 percent and barely reaches the bloodstream. Systemic absorption from creams and gels is minimal enough that the drug is considered relatively safe for general use in acne and photoaging, with the main side effects being local skin irritation.

Oral tretinoin capsules, by contrast, deliver the drug directly into the bloodstream at doses designed to saturate the body’s retinoic acid receptors. The standard dose for APL is 45 milligrams per square meter per day, divided into two doses. At these levels, the systemic effects are profound, which is why the side-effect profile looks nothing like what a dermatology patient would expect. Differentiation syndrome, raised intracranial pressure, liver toxicity, and teratogenicity are all consequences of high systemic exposure. A patient on topical tretinoin for acne and a patient on oral tretinoin for APL are taking the same molecule but living in very different risk landscapes.

Pharmacies sometimes dispense oral tretinoin capsules with labels that confuse patients, particularly when the brand name Vesanoid (oral, for leukemia) gets mixed up with Retin-A (topical, for skin). Healthcare teams generally take care to specify the route, formulation, and indication clearly, but the potential for mix-ups is real enough that it has been flagged as a medication safety concern.

Storage and Handling Considerations

Tretinoin capsules are sensitive to light and heat. The drug degrades when exposed to sunlight or high temperatures, which means capsules need to be stored in their original packaging in a cool, dark place. This matters not just for patients keeping the medication at home but also for healthcare systems in tropical climates, where cold-chain logistics for medications can be unreliable. A degraded capsule may deliver a lower effective dose without any outward sign of the problem, which in a disease as aggressive as APL could mean the difference between remission and treatment failure.

Handling is another practical concern. Because tretinoin is classified as a hazardous drug, pharmacists and nurses preparing doses, especially when extracting capsule contents for tube administration, should use appropriate protective equipment. Pregnant staff members should avoid handling the capsules entirely, given the drug’s teratogenic potential. These precautions mirror the handling protocols for traditional chemotherapy, even though tretinoin’s mechanism of action is fundamentally different from cytotoxic drugs.